Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04692688 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
A Phase 2 study, sponsored by Ocuphire Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT04692688 is a Phase 2 study that has completed, run by Ocuphire Pharma. The registered enrollment target is 103 participants.
The verdict
NCT04692688, a Phase 2 study, has completed, sponsored by Ocuphire Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
Interventions
- DRUG Placebo
- DRUG APX3330
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2021-04-08 |
| Est. Completion | 2023-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04692688
The ClinicalTrials.gov registry entry for NCT04692688 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocuphire Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04692688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04692688 about?
NCT04692688 is a clinical study titled "Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy". The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
What is the current status of trial NCT04692688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2021-04-08. Estimated completion is 2023-01-25.
What interventions are being tested in trial NCT04692688?
The interventions under investigation include: Placebo (DRUG), APX3330 (DRUG).
Who is sponsoring clinical trial NCT04692688?
This trial is sponsored by Ocuphire Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.